Convenient 6-month dosing schedule

OCREVUS is administered twice yearly as a 600 mg IV infusion

  • The initial 600 mg dose is administered as 2 separate intravenous infusions given over approximiately 2.5 hours*: first as a 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion
  • Subsequent doses thereafter administered over approximately 3.5 hours* as a single 600 mg intravenous infusion every 6 months (24 weeks)
    • The first subsequent dose is administered 24 weeks after infusion 1 of the initial dose and is administered over the same period as a single 600 mg intravenous infusion. Dose modifications may be necessary in response to severity of infusion reactions
  • Observe the patient for at least 1 hour after the completion of the infusion

*Infusion may take longer if the infusion is interrupted or slowed.

Doses of OCREVUS must be separated by at least 20 weeks.

Delayed or missed doses

  • If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose
  • Reset the dose schedule to administer the sequential dose 6 months (24 weeks) after the missed dose is administered

Pretreatment evaluation

  • Hepatitis B virus screening should be performed in all patients before initiation of treatment with OCREVUS
  • Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of OCREVUS for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of OCREVUS for non-live vaccines

Preparation before every infusion

Infection assessment
  • Determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until infection resolves
Recommended premedication
  • Premedicate with 100 mg IV methylprednisolone (or equivalent) approximately 30 minutes before each infusion
  • Premedicate with an antihistamine (eg, diphenhydramine) approximately 30 to 60 minutes prior to each OCREVUS infusion
  • The addition of an antipyretic (eg, acetaminophen) may also be considered

Recommended dose, infusion rate, and infusion duration for RMS and PPMS

*Infusion may take longer if the infusion is interrupted or slowed
Administer the subsequent dose 6 months after infusion 1 of initial dose

Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride injection, to a final drug concentration of approximately 1.2 mg/mL

See how to manage infusion-related reactions (IRRs) in your patients

View the full Prescribing Information for complete Dosage and Administration

OCREVUS Dosing and Administration Guide

Download this useful resource designed to provide guidance to MS care teams and infusion centers.

Patient assistance options

Genentech can help identify the most appropriate assistance option to help your patient get the Genentech medicines he or she needs.